PURPOSE:To investigate the expression of human beta-defensin 2(HBD-2)and human beta-defensin 3(HBD-3)in tissue engineered oral mucosa equivalents under the stimulation of Escherichia coli lipopolysaccharide(LPS)and recombinant human interleukin-1(IL-1β),and to evaluate the possibility of using tissue engineered oral mucosa in the treatment of infectious oral diseases.METHODS:Real-time fluorescent quantitative reverse transcription PCR(RT-qPCR)and Western blot were used to evaluate the mRNA and protein expression of HBD-2 and HBD-3 in tissue engineered oral mucosa substitutes under the stimulation of LPS and IL-1β.SPSS 26.0 software package was used for data analysis.RESULTS:LPS and IL-1β stimulated the mRNA and protein expression of HBD-2 and HBD-3 in tissue-engineered oral mucosa,and showed a dose-dependent increase after 24 hours of culture(P＜0.05).At 100 ng/mL,LPS induced HBD-2 mRNA by about 2.7-fold and HBD-3 mRNA by about 5-fold,respectively.The maximal production of HBD-2 mRNA was about 1.6-fold and HBD-3 about 4.8-fold by 20 ng/mL IL-1β.As to the results of western blot analysis,both LPS and IL-1β induced HBD-2 protein secretion at the maximal concentration in this study.HBD-3 protein was hardly observed without any treatment.After incubation with LPS and IL-1β,HBD-3 protein was significantly up-regulated(P＜0.05).CONCLUSIONS:Tissue engineered oral mucosa equivalents are armed with defense activity against invading mi-croorganisms in a sense,which may provide a therapy substitute for infectious oral diseases in the future.
万方数据
维普
